PURPOSE OF REVIEW: To summarize the recent advancements in common variable immune deficiency (CVID), specifically CVID genetics, clinical discoveries and treatment implications. RECENT FINDINGS: Large genomic studies have implicated new genes in the pathogenesis of CVID, and basic science studies have contributed to our knowledge of potential mechanisms. Cohort studies have further defined the immunologic parameters and clinical presentation of CVID, as well as the factors that contribute to morbidity and mortality in this disease. Immunoglobulin remains the mainstay of treatment, although there may be a role for immunosuppression and other therapies. SUMMARY: CVID is a genotypically and phenotypically heterogeneous primary immune deficiency, the genetic and clinical characteristics of which are under active investigation. Further, discovery may yield important new treatment protocols that can continue to reduce the morbidity and mortality from this disease.
PURPOSE OF REVIEW: To summarize the recent advancements in common variable immune deficiency (CVID), specifically CVID genetics, clinical discoveries and treatment implications. RECENT FINDINGS: Large genomic studies have implicated new genes in the pathogenesis of CVID, and basic science studies have contributed to our knowledge of potential mechanisms. Cohort studies have further defined the immunologic parameters and clinical presentation of CVID, as well as the factors that contribute to morbidity and mortality in this disease. Immunoglobulin remains the mainstay of treatment, although there may be a role for immunosuppression and other therapies. SUMMARY:CVID is a genotypically and phenotypically heterogeneous primary immune deficiency, the genetic and clinical characteristics of which are under active investigation. Further, discovery may yield important new treatment protocols that can continue to reduce the morbidity and mortality from this disease.
Authors: Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz Journal: J Allergy Clin Immunol Pract Date: 2015-11-07
Authors: L Klimek; A Chaker; C Matthias; A Sperl; P Gevaert; P Hellings; B Wollenberg; M Koennecke; J Hagemann; J Eckrich; S Becker Journal: HNO Date: 2019-09 Impact factor: 1.284
Authors: Shoichiro Tsuji; Lucas Stein; Nobuhiko Kamada; Gabriel Nuñez; Richard Bram; Bruce A Vallance; Ana E Sousa; Jeffrey L Platt; Marilia Cascalho Journal: J Clin Invest Date: 2014-10-01 Impact factor: 14.808
Authors: A A J M van de Ven; W J M Janssen; L S Schulz; A M van Loon; K Voorkamp; E A M Sanders; J G Kusters; S Nierkens; M Boes; A M J Wensing; J M van Montfrans Journal: J Clin Immunol Date: 2014-08-19 Impact factor: 8.317
Authors: Rita R Barbosa; Susana L Silva; Sara P Silva; Alcinda C Melo; M Conceição Pereira-Santos; João T Barata; Lennart Hammarström; Marília Cascalho; Ana E Sousa Journal: J Clin Immunol Date: 2014-05-09 Impact factor: 8.317
Authors: E Taraldsrud; B Fevang; P Aukrust; K H Beiske; Y Fløisand; S Frøland; H Rollag; J Olweus Journal: Clin Exp Immunol Date: 2014-03 Impact factor: 4.330